SUMMARY Transiliac biopsies from 34 female patients with corticosteroid treated chronic active hepatitis have been examined to determine the contributions made by decreased bone formation and increased bone resorption to bone loss associated with this condition and to determine the structural basis of the bone loss. Mean wall thickness was significantly reduced when compared with control values (p<0.001) as was the bone formation rate at tissue (p<O.OO5) and basic multicellular unit (p<0005) level. The osteoid maturation period and the bone formation period were significantly prolonged (p<0-02 and 0.05). The total resorption surfaces were significantly increased (p<0.02) but the mean interstitial bone thickness was normal. The mean trabecular plate thickness was significantly reduced (p<0.005). These findings indicate that decreased bone formation plays a major role in bone loss associated with corticosteroid treated chronic active hepatitis and that the structural basis of bone loss is trabecular thinning.
Reduced trabecular and cortical bone mass have recently been reported in patients with autoimmune chronic active hepatitis (CAH) on maintenance corticosteroids. 12 Corticosteroids are known to induce bone loss, probably as a result both of direct inhibition of bone formation and an increase in parathyroid hormone mediated bone resorption secondary to calcium malabsorption;`8 non-steroid treated chronic liver disease is also associated with an increased prevalence of osteoporosis.'3 Detailed bone histomorphometric studies in patients with chronic cholestatic or alcoholic liver disease have shown that reduced bone formation plays a major role in bone loss, although increased resorption may also contribute;"'6 in addition, the mechanism of bone loss in chronic cholestatic liver disease at the microanatomic level appears to be trabecular thinning rather than erosion through and removal of whole trabecular elements. 5 The pathophysiology of bone loss associated with steroid treated CAH has not been reported. In this study we have examined the changes in bone histomorphometry and microanatomic structure in iliac crest biopsies from 34 female patients with CAH receiving longterm corticosteroid therapy.
Methods

PATIENTS
The 34 female patients, aged 20-66 years (19 postmenopausal), fulfilled internationally agreed criteria for autoimmune CAH. 7 Twenty two of the 34 patients had biopsy proven cirrhosis, documented in one or more biopsies, over a period of one to 12 years. At the time of study all patients were in biochemical and histological remission as defined by a serum aspartate transaminase (SGOT) level of less than 40 IU/l and a liver biopsy appearance of chronic persistent hepatitis or an inactive cirrhosis without piecemeal necrosis. All patients had received prednisolone for a minimum period of one year (median 3-6 years; range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and were maintained on doses of 5 mg/day in two patients, 7-5 mg/day (8), 10 mg/ day (23) , and 12-5 mg/day (1). Thirty one patients in addition were receiving azathioprine 50-100 mg/day. 378 The results of biochemical measurements are shown in Table 2 . Serum calcium was decreased in two patients both of whom were premenopausal. Serum 25-hydroxyvitamin D concentrations were normal in all but three patients in whom subnormal levels (less than 12 nm/litre) were found. Two premenopausal patients had raised iPTH levels. The mean fasting urinary calcium creatinine ratio was not significantly different from controls despite six patients (five Table 2 Biochemical data in patients Results are expressed as mean (SD); Conversion from SI to traditional units; serum calcium 1 mmol/l=4 mg/100 ml; serum 25-hydroxyvitamin D 2.5 nmol/l=1 ng/ml; serum immunoreactive parathyroid hormone 243 pmol/l =1 ng/ml; fasting urinary calcium/ creatinine ratio 1 mmol/l calcium=4 mg/100 ml, 1 Rmol/l creatine =0-0113 mg/100 ml. (p<0.005) when compared with controls as were the bone formation rate at tissue level (p<0005) and BMU level (p<0 005). The osteoid maturation period (p<0.02) and bone formation period (p<005) were significantly prolonged when compared with the controls.
When patients were separated into those with and without cirrhosis, although age and mean daily dose of prednisolone and azathioprine were comparable in both groups, no statistically significant difference was found between the two groups with respect to any of the histological parameters measured.
Weak correlations were only found between maintenance dose of prednisolone and total resorption surfaces (r=0.4; p<005) and dose duration of corticosteroid therapy and trabecular bone volume (r=-0.39; p<0.05) and cortical plate thickness (r=-0.36; p<0.05).
Discussion
Our results confirm previous reports2 of cortical and trabecular osteoporosis in patients with corticosteroid treated chronic active hepatitis and show that reduced bone formation is a major contributory factor. The reduction in trabecular bone volume may have been underestimated as the decreased cortical plate thickness also observed probably resulted from endosteal resorption, creating new trabeculae which would have been included in the area for quantification of trabecular bone volume. Nevertheless, 14% of the patients studied had a value for trabecular bone volume within the vertebral fracture threshold range of 11(3)%. 23 At a microanatomic level, trabecular bone loss may be caused by either a thinning of the trabeculae, with preservation of trabecular architecture, or by erosion through and removal of trabeculae, thus reducing trabecular interconnectedness, or to a combination of both (Fig. 3) . This study shows that the structural basis for bone loss in corticosteroid treated CAH is trabecular thinning rather than erosion through and removal of trabecular plates. Thus the mean value for mean trabecular plate thickness was significantly reduced in the patient group without any significant accompanying change in mean trabecular plate separation and density, indicating preservation of the trabecular structural pattern. This pattern of bone loss is similar to that observed in patients with primary biliary cirrhosis'5 and jejunoileal bypass26 and may be associated with a lower fracture risk than bone loss involving loss of trabecular plates and reduced interconnectedness of trabeculae.27
Mean wall thickness was significantly lower in the patient group, indicating reduced bone formation. Further evidence of low bone formation comes from the finding of a reduced bone formation rate at tissue and cellular level and the presence of only single tetracycline labelling in four patients. Although the mean osteoid seam width was normal in the patients, this, in association with a decreased mineralisation rate and prolonged osteoid maturation period indicates a reduced osteoblastic appositional rate and decreased matrix synthesis, as under conditions of normal matrix synthesis delayed mineralisation would result in an increased osteoid seam width. Because the bone formation period was increased in the patients, it seems likely that impaired function of osteoblasts rather than a reduction in lifespan was responsible for the impairment of matrix synthesis and mineralisation.
The mean total resorption surface was significantly higher in patients than in controls, although only small rises were seen. Measurement of total resorption surface, however, does not indicate resorption rate and values may be raised as a result of reduced bone formation leading to incomplete filling of normal resorption cavities. The biochemical indicators of bone resorption measured in this study, namely serum iPTH and urinary calcium/creatinine ratio were similar in patients and controls, although two patients had raised iPTH concentrations and urinary calcium creatinine ratios were increased in five patients. The most compelling evidence against a contribution by increased bone resorption to the bone loss seen comes from the measurements of mean interstitial bone thickness, which reflect the amount of bone at the BMU level which has undergone resorption in the past (Fig. 2) , values for mean interstitial bone thickness in the patient group being extremely similar to those of controls. This differs from the finding that, in patients with primary biliary cirrhosis, values for mean interstitial bone thickness were significantly decreased, indicating that resorption had been increased in the past. '5 The relative contributions made by liver disease and corticosteroid therapy to the bone loss seen cannot be assessed in a study of this kind. Most patients in this study were also receiving azathioprine; however, no effect of this drug on bone remodelling has been reported. The decreased bone formation and increase in total resorption surfaces observed in the present study are compatible with changes reported in corticosteroid induced bone loss in patients with normal liver function,35828 as well as in non-steroid treated patients with chronic liver disease." 4 The evidence for increased activation of remodelling sites, however, reported in some studies of corticosteroid osteoporosis, with an increase not only in total resorption surface but also in osteoid surface4 21 and tetracycline labelled surfaces28 was not encountered in the present study. The observation that spinal trabecular bone mineral content, measured by quantitative computed tomography is lower in patients with steroid treated CAH than in those with other forms of chronic liver disease29 provides indirect evidence that corticosteroid therapy may exacerbate the bone loss associated with chronic liver disease. The demonstration that bone loss associated with steroid treated CAH is predominantly a result of decreased bone formation suggests that the role of agents which increase bone formation -for example, sodium fluoride, should be evaluated in these patients. 
